Opitel A Tablet contains a combination of Telmisartan 40 mg and Amlodipine 5 mg, indicated for the management of hypertension. Telmisartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, leading to vasodilation and reduction in blood pressure. Amlodipine, a dihydropyridine calcium channel blocker, inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in peripheral arterial vasodilation and decreased systemic vascular resistance. The combined use of these agents provides complementary mechanisms to effectively control high blood pressure, reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. Opitel A is typically prescribed when monotherapy with either agent is insufficient to achieve target blood pressure levels. It is important to monitor blood pressure regularly and assess for potential side effects, including dizziness, peripheral edema, hypotension, and renal function impairment. Caution is advised in patients with hepatic or renal impairment and those with a history of angioedema. This combination therapy should be used under medical supervision to optimize antihypertensive efficacy and minimize adverse effects.